Etrolizumab in moderate-to-severe ulcerative colitis

The Lancet

Volumn 384, Issue 9940, 2014, Pages 285-286

  Armuzzi, Alessandro ^a   Felice, Carla ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETROLIZUMAB; IMMUNOSUPPRESSIVE AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VEDOLIZUMAB; INTEGRIN; INTEGRIN ALPHA4 BETA7; UNCLASSIFIED DRUG; UVOMORULIN;

BIOLOGICAL THERAPY; COMPARATIVE EFFECTIVENESS; DRUG MECHANISM; HUMAN; LOADING DRUG DOSE; NOTE; PRIORITY JOURNAL; REMISSION; TREATMENT PLANNING; TREATMENT RESPONSE; ULCERATIVE COLITIS; B LYMPHOCYTE; COLON BIOPSY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INTESTINE CRYPT; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE;

EID: 84904857804     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60529-8     Document Type: Note

References (10)

1. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial. Lancet 2014; published online May 9. http://dx.doi.org/10.1016/S0140-6736(14)60661-9.
2. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut 2013; 62: 1122-30.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
4. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
5. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology 2014; 146: 85-95.
6. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
7. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-57.
8. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. Review article: Anti-adhesion therapies for infl ammatory bowel disease. Aliment Pharmacol Ther 2014; 39: 579-94.
9. Cassani B, Villablanca EJ, Quintana FJ, et al. Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice. Gut 2011; 141: 2109-18.
10. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med 2005; 352: 2499-507.